The IRIS team focuses on the physiopathology of the ischemia-reperfusion syndromes in the heart, kidney and brain, by combining fundamental, translational and clinical approaches.
Our strategy relies on three main aims:
 |
Although important therapeutic progress has been made over the last two decades, ischemic pathologies such as myocardial infarction and stroke remain one of the first causes of death worldwide. Due to the aging of the population and the progression of comorbidity factors like diabetes, obesity and arterial hypertension, the occurrence of ischemia-reperfusion syndromes should continue and even worsen in the next decades. |
The previous Team 5 “Cardioprotection” in the CarMeN laboratory, funded by Pr Michel Ovize, has developed its research around ischemic cardiopathies. More recently, our team has widened its expertise to the cerebral and renal ischemic diseases thanks to the recruitment of experts in these fields.
Our new team IRIS (Ischemia-Reperfusion Injury Syndromes), created by the HCERES in January 2021, gathers a fundamental research group and a clinical research group, which drive together an ambitious translational research program.
The clinical research group is composed of cardiologists, neurologists, nephrologists, surgeons and anesthetists-resuscitators who work in several hospitals from the Hospices Civiles de Lyon. Its main objective is to conduct clinical trials aiming to test the effect of therapeutic molecules on ischemia-reperfusion syndromes in collaboration with the Clinical Center of Investigation of Lyon. They have acquired a strong experience in the implementation and the leading of clinical trials ranging from proof-of-concept, multicentric, randomized, controlled, to phase III trials, which are valorized by high impact factor publications and institutional hospital-university contracts (FHU, IHU, RHU).
The fundamental research group is made of INSERM and CNRS researchers, university teaching-researchers and clinicians-researchers, covering a wide range of expertise from molecular biology and biophysics to human physiopathology through medical imaging and in vivo experimentation.
These two groups work conjointly to give rise to a translational research based on two complementary approaches: “from bench to bedside” and “from patient to bench”.
In the “from bench to bedside” approach, the fundamental research results are obtained from our in vitro and in vivo models, and can lead in fine to clinical trials in humans, as already done for Cyclosporine A in the treatment of myocardial infarct, cardiac arrest, stroke and renal ischemia.
More recently, the second approach, termed “from patient to bench”, has been set up in the team. It aims to first exploit the biobanks (stocked in the Biological Resources Center Neurobiotech in Lyon) composed of tissue and blood samples from patients who underwent an ischemic event, and to identify new prognostic and diagnostic markers.
Secondly, the relevance of our animal models is tested and adapted to verify that they reproduce the variations observed in patients.
Finally, a fundamental research project is created to understand how the expression of this marker and if an early pharmacological targeting of its regulation pathway could lead to the identification of a new therapeutic target.
– ischemia-reperfusion, reperfusion injury, myocardial infarction, cardiac arrest, stroke, cardiorenal syndrome, cardiometabolic syndrome, inflammation, conditioning, therapeutic hypothermia, biomarkers, bioenergetics, permeability transition pore, calcium, sarco-endoplasmic reticulum, mitochondria, MAMs, diabetic cardiomyopathy.
We are developing preventive strategies and new treatments for better patient care. Researchers are counting on you!
Support research
